Generic Nexium to Boost Dr Reddy's Bottlomline: Surjit Pal
Surjit Pal, pharma analyst at Prabhudas Lilladher, told NDTV that Dr Reddy's Lab may capture 10-12 per cent market share in Nexium generics in the US in a year, which may add Rs 12 to its annual earnings per share.
